Summary
The product AROMASIN 10, manufactured by Unique Pharma, was independently tested to verify its authenticity and potency. The sample, identified by batch number UN6337, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Exemestane, with a concentration of 11.65 mg, exceeding the labeled claim of 10 mg by 16.5%.
The testing process commenced on 27 February 2024, with the sample received on 07 March 2024, and the analysis completed on 08 March 2024. While the results confirm the presence of a slightly higher-than-labeled concentration, it is important to consider that reseller-submitted samples may represent optimal batches, potentially differing from general market consistency. Independent third-party testing remains crucial to verify product consistency across multiple batches. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: AROMASIN 10
- Active Ingredient: Exemestane
- Batch Number: UN6337
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #39490
- Testing Ordered: 27 February 2024
- Sample Received: 07 March 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 10 mg (as stated on the label)
- Measured Concentration: 11.65 mg
- Accuracy: 116.5% (16.5% above the label claim)
- Variance: +16.5%
Verification Details
- Verification URL: www.janoshik.com/tests/39490_CVWWPIET6AXF
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis confirms that the tested product exceeds its labeled claim, suggesting a higher dose per tablet than advertised. However, since the sample was submitted and funded by the reseller Opitropin.EU, there is a possibility of selective sampling of high-quality batches. For broader product reliability, further independent testing across multiple batches is recommended.
Conclusion
The analysis of AROMASIN 10 confirms a higher-than-expected measured concentration of 11.65 mg, reflecting an overdose of 16.5%. This suggests strong quality control for this particular batch; however, it highlights the need for additional testing to ensure consistent dosing across production batches. This report aims to support educational and harm reduction efforts, enabling consumers to make informed choices.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it still provides useful insights when critically assessed alongside independent third-party results. Consumers are encouraged to interpret this data responsibly.
